KR100330138B1 - 헬리코박터 파이로리의 세포 결합을 저해하는 인삼뿌리에서 분리된 산성다당류 및 이를 함유하는 위장병 예방 및 치료용 조성물 - Google Patents
헬리코박터 파이로리의 세포 결합을 저해하는 인삼뿌리에서 분리된 산성다당류 및 이를 함유하는 위장병 예방 및 치료용 조성물 Download PDFInfo
- Publication number
- KR100330138B1 KR100330138B1 KR1019990047531A KR19990047531A KR100330138B1 KR 100330138 B1 KR100330138 B1 KR 100330138B1 KR 1019990047531 A KR1019990047531 A KR 1019990047531A KR 19990047531 A KR19990047531 A KR 19990047531A KR 100330138 B1 KR100330138 B1 KR 100330138B1
- Authority
- KR
- South Korea
- Prior art keywords
- helicobacter
- acidic
- present
- ginseng
- helicobacter pylori
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 229940107131 ginseng root Drugs 0.000 title claims abstract description 10
- 241000589989 Helicobacter Species 0.000 title abstract description 26
- 229920001282 polysaccharide Polymers 0.000 title abstract description 26
- 230000001225 therapeutic effect Effects 0.000 title abstract description 5
- 230000005764 inhibitory process Effects 0.000 title description 2
- 230000002378 acidificating effect Effects 0.000 title 1
- 230000003449 preventive effect Effects 0.000 title 1
- 229920001284 acidic polysaccharide Polymers 0.000 claims abstract description 37
- 150000004805 acidic polysaccharides Chemical class 0.000 claims abstract description 37
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 21
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 21
- 239000002253 acid Substances 0.000 claims abstract description 15
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 4
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 8
- 239000008055 phosphate buffer solution Substances 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- 238000004255 ion exchange chromatography Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 abstract description 25
- 150000004804 polysaccharides Chemical class 0.000 abstract description 24
- 235000008434 ginseng Nutrition 0.000 abstract description 17
- 241000208340 Araliaceae Species 0.000 abstract description 15
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 15
- 208000010643 digestive system disease Diseases 0.000 abstract description 4
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract description 4
- 230000035931 haemagglutination Effects 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 240000004371 Panax ginseng Species 0.000 abstract 2
- 235000002789 Panax ginseng Nutrition 0.000 abstract 2
- 239000006286 aqueous extract Substances 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 description 17
- 235000014633 carbohydrates Nutrition 0.000 description 16
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 230000002776 aggregation Effects 0.000 description 12
- 238000004220 aggregation Methods 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000000287 crude extract Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010059820 Polygalacturonase Proteins 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 3
- 230000005859 cell recognition Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 108010093305 exopolygalacturonase Proteins 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000589562 Brucella Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 101100059291 Dictyostelium discoideum cbpE gene Proteins 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- -1 albino Chemical compound 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- OXNGKCPRVRBHPO-VIXGDSECSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2NC(C)=O)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O OXNGKCPRVRBHPO-VIXGDSECSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- YMFBFFPJRABBPE-BTVCFUMJSA-N ethanol;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound CCO.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O YMFBFFPJRABBPE-BTVCFUMJSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000005583 trifluoroacetylation reaction Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Sustainable Development (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
분획 | 탄수화물(%) | 유로닌산(%) | 단백질(%) | 단당류 조성비(포도당: 갈락토스: 아라비노스) |
조추출물 | 42.9 | 12.5 | 2.9 | 대부분 포도당 |
에탄올침전 | 45.2 | 15.0 | 12.6 | 10 : 1 : 매우적은량 |
산성다당류 | 42.1 | 29.3 | 12.4 | 2.3 : 1 : 0.7 |
중성다당류 | 44.7 | 5.0 | 4.7 | 대부분 포도당 |
분획 | 최소저해활성 농도(mg/mL) |
조추출물 | 1.2 |
에탄올침전 | 0.5 |
중성다당류 | 2.0에서도 저해활성 없음 |
산성다당류 | 0.25 |
효소처리된 산성다당류 | 4.0에서도 저해활성 없음 |
Claims (7)
- 인삼뿌리를 인산완충용액으로 균질화시킨 다음 원심분리하여 얻은 침전물을 60∼100℃의 증류수로 추출한 후 상등액을 증류수로 투석하고 7배 부피의 에탄올로 침전시켜, 침전물을 인산 완충용액에 용해, 투석한 후 이온교환 크로마토크래피를 하여 이에 결합되는 분획이며, 유로닌산이 25∼35중량% 포함되어 있는 것을 특징으로 하는 헬리코박터 파이로리의 세포결합 저해활성이 있는 산성다당류.
- 삭제
- 제1항의 산성다당류를 유효성분으로 함유하는 것을 특징으로 하는 위장병 예방 및 치료용 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990047531A KR100330138B1 (ko) | 1999-10-29 | 1999-10-29 | 헬리코박터 파이로리의 세포 결합을 저해하는 인삼뿌리에서 분리된 산성다당류 및 이를 함유하는 위장병 예방 및 치료용 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990047531A KR100330138B1 (ko) | 1999-10-29 | 1999-10-29 | 헬리코박터 파이로리의 세포 결합을 저해하는 인삼뿌리에서 분리된 산성다당류 및 이를 함유하는 위장병 예방 및 치료용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010039228A KR20010039228A (ko) | 2001-05-15 |
KR100330138B1 true KR100330138B1 (ko) | 2002-03-27 |
Family
ID=19617663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990047531A KR100330138B1 (ko) | 1999-10-29 | 1999-10-29 | 헬리코박터 파이로리의 세포 결합을 저해하는 인삼뿌리에서 분리된 산성다당류 및 이를 함유하는 위장병 예방 및 치료용 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100330138B1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100379189B1 (ko) * | 2000-12-14 | 2003-04-08 | 학교법인고려중앙학원 | 헬리코박터 파이로리에 의한 위질환 치료제용 조성물 및그 탐색방법 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100415591B1 (ko) * | 2001-03-08 | 2004-01-16 | 남양유업 주식회사 | 위장내 헬리코박터 피로리 감염균의 감소 및 증식억제능이 있는 요구르트 조성물 |
KR100423521B1 (ko) * | 2001-08-29 | 2004-03-18 | 네비온 주식회사 | 인삼다당체를 함유하는 화장품 조성물 |
KR20040046382A (ko) * | 2002-11-27 | 2004-06-05 | (주)서림식품 | 인삼박으로부터 다당체를 분리하는 방법 |
KR20040081932A (ko) * | 2003-03-17 | 2004-09-23 | 설혜영 | 홍삼/인삼 신속추출 및 농축액 증대 |
KR101042903B1 (ko) * | 2004-12-03 | 2011-06-20 | 주식회사 대우일렉트로닉스 | 냉장고 도어스위치와 일체화된 중간힌지구조 |
KR100797016B1 (ko) * | 2007-01-25 | 2008-01-22 | 주식회사 코인텍 | 면역증강 활성을 나타내는 인삼다당체 고농축정제액과 그제조방법 |
KR101434471B1 (ko) * | 2012-10-24 | 2014-08-27 | (주)에스.앤.디 | 천연물 유래 당 배합체를 이용한 위염 및 암 예방 조성물과 그 제조방법 |
CN115651088A (zh) * | 2022-08-23 | 2023-01-31 | 辽宁成大生物股份有限公司 | 人参总多糖的制备方法和应用、人参总多糖疫苗佐剂及其疫苗组合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950014139A (ko) * | 1993-11-05 | 1995-06-15 | 박명규 | 인삼 또는 알콜추출 인삼박으로부터 산성 다당체를 분리하는 방법 |
-
1999
- 1999-10-29 KR KR1019990047531A patent/KR100330138B1/ko active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950014139A (ko) * | 1993-11-05 | 1995-06-15 | 박명규 | 인삼 또는 알콜추출 인삼박으로부터 산성 다당체를 분리하는 방법 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100379189B1 (ko) * | 2000-12-14 | 2003-04-08 | 학교법인고려중앙학원 | 헬리코박터 파이로리에 의한 위질환 치료제용 조성물 및그 탐색방법 |
Also Published As
Publication number | Publication date |
---|---|
KR20010039228A (ko) | 2001-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jin et al. | Structure characterization of a polysaccharide extracted from noni (Morinda citrifolia L.) and its protective effect against DSS-induced bowel disease in mice | |
KR100602841B1 (ko) | 헬리코박터 파이로리의 세포결합 저해활성을 갖는 녹차에서분리된 산성 다당체와 이를 함유하는 소화성 질환 예방 및치료용 조성물 | |
Scoparo et al. | Chemical characterization of heteropolysaccharides from green and black teas (Camellia sinensis) and their anti-ulcer effect | |
KR100330138B1 (ko) | 헬리코박터 파이로리의 세포 결합을 저해하는 인삼뿌리에서 분리된 산성다당류 및 이를 함유하는 위장병 예방 및 치료용 조성물 | |
US4855284A (en) | Calcium and magnesium complexes of phytohemagglutinin-polyheteroglycans, their preparation and pharmaceutical formulations | |
Zhang et al. | A glycoprotein from mountain cultivated ginseng: Insights into their chemical characteristics and intracellular antioxidant activity | |
CN103382229A (zh) | 一种具有免疫调节作用的新型海胆黄多糖的制备方法及结构鉴定 | |
EP0475383B1 (en) | Polysaccharide composition or polysaccharide having heparinoid activity, process for producing the same, and anticoagulant containing the same as active ingredient | |
JPS5932480B2 (ja) | 新規な糖蛋白複合体 | |
CN112076207A (zh) | 高分子量蛹虫草多糖及其制备方法和在制备抗补体药物中的用途 | |
CN115414379B (zh) | 三七多糖sqp20在制备治疗肠损伤与炎性浸润的药物的应用 | |
KR20240125922A (ko) | 다당류 트립신 억제제 및 이의 제조 방법 | |
Ingólfsdóttir | Bioactive compounds from Iceland moss | |
KR100379189B1 (ko) | 헬리코박터 파이로리에 의한 위질환 치료제용 조성물 및그 탐색방법 | |
JP2005526142A (ja) | Coriolusversicolorから取得した、検証可能な経口吸収性を有する免疫調節ペプチド結合グルカンの調製および標定 | |
EP2905026B1 (en) | Peyer's patch activator | |
CN110498863B (zh) | 薜荔叶多糖及其制备方法和在制备抗补体药物中的用途 | |
CN113603802A (zh) | 一种马鞭草多糖的制备方法与应用 | |
KR100468649B1 (ko) | 항보체 활성을 갖는 운지버섯 자실체 유래의 다당체 및 그분리방법 | |
KR100573631B1 (ko) | 포피로모나스 진지발리스의 세포결합을 저해하는인삼뿌리에서 분리된 산성다당류 및 이를 함유하는 구강치주질환 예방 및 그 치료용 조성물 | |
CN112915198A (zh) | 一种含有溶菌酶的治疗牛皮癣的软膏 | |
KR100630479B1 (ko) | 아카란 황산을 유효성분으로 함유하는 헬리코박터 파일로리감염 억제용 조성물 | |
CN114316081B (zh) | 一种具有抑制SARS-CoV-2活性的长茎葡萄蕨藻硫酸化多糖及其制备方法和应用 | |
Chionglo et al. | Structural basis of group G streptococcal antigenicity | |
Lin et al. | Pharmacological bioactivity of enzymatically bio-transformed ginsenosides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130123 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20140312 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20160311 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20170107 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20180313 Year of fee payment: 17 |
|
FPAY | Annual fee payment |
Payment date: 20190302 Year of fee payment: 18 |